San Diego, California and Reykjavik, Iceland (ots/PRNewswire) -
- Continues Research to Validate Significance of SEQUENOM's
Portfolio of Breast Cancer Genetic Discoveries
SEQUENOM, Inc. (NASDAQ: SQNM) and Iceland Genomics Corporation
(Iceland Genomics), a privately-held company, entered into a research
collaboration to analyze SEQUENOM's proprietary panels of genetic
markers associated with breast and prostate cancer in Icelandic
patient samples. The results of this collaboration could provide
further validation of SEQUENOM's genetic markers predisposing for
breast and prostate cancer, and improve the understanding of the role
of these genetic markers in disease onset, progression and
SEQUENOM's proprietary genetic markers were discovered through a
series of genome-wide association studies and subsequently replicated
in multiple independent clinical collections. Among the markers to be
studied in the Icelandic population are SNPs (single nucleotide
polymorphisms) from the ICAM and the NuMA gene regions. SEQUENOM and
Iceland Genomics will jointly analyze the resulting data to determine
to what extent SEQUENOM's disease predisposition markers are
associated with specific clinical endpoints.
"The collaboration between our two companies may lead to important
breast and prostate cancer diagnostic and prognostic applications in
the field of molecular medicine. The study should provide insight to
what extent genetic markers that predispose an individual to a higher
disease risk affect disease progression and therapeutic outcome,"
stated Steve Zaniboni, SEQUENOM's acting Chief Executive Officer.
"SEQUENOM has identified and validated more than 60 high confidence
candidate gene regions in 11 major disease areas. This collaboration
is part of a program to establish the diagnostic value of SEQUENOM's
disease gene portfolio beyond disease predisposition."
"Iceland is a very exciting and rewarding place for performing
genetic analysis of complex diseases such as cancer. Comprehensive
clinical data combined with the participation and goodwill of
Icelanders and the clinical community provides an unparalleled basis
for a successful research effort," said Dana Hosseini, Iceland
Genomics' Chief Executive Officer. "This agreement is part of our
long term strategic effort to utilize our cancer research program to
develop results that can be translated into therapeutic benefits for
Iceland Genomics will utilize its large collections of breast and
prostate cancer patient samples and clinical databases to test and
validate SEQUENOM's markers. The results of the collaboration are
expected to increase the utility and value of Iceland Genomics'
cancer genomic database. SEQUENOM has commercialization rights for
products developed as a result of the collaboration and Iceland
Genomics is entitled to receive royalties from sales of those
About Iceland Genomics Corporation
Iceland Genomics Corporation (Iceland Genomics) is a privately
held cancer biology company using an innovative 'clinical genomics'
approach to understand the underlying mechanisms of cancer, isolate
and characterize new therapeutic targets for cancer, assess outcomes
of specific therapies in genetically defined subcategories of cancer
patients and optimize clinical trials for success. Iceland Genomics
was incorporated in the State of Delaware in October 1998, and is the
sole owner of an Icelandic subsidiary called UVS. Iceland Genomics is
one of several genomics-based biotechnology companies operating in
Iceland and the only company that solely focuses on cancer biology.
SEQUENOM is committed to providing the best genetic analysis
products that translate genomic science into superior solutions for
biomedical research, molecular medicine and agricultural
applications. The Company's proprietary MassARRAY system is a
high-performance DNA analysis platform that efficiently and precisely
measures the amount of genetic target material and variations
therein. The system is able to deliver reliable and specific data
from complex biological samples and from genetic target material that
is only available in trace amounts.
SEQUENOM(R) and MassARRAY(R) are registered trademarks of
ots Originaltext: Sequenom, Inc.
Im Internet recherchierbar: http://www.newsaktuell.ch
Amy Caterina, SEQUENOM, Inc., Investor Relations, +1-858-202-9033,
email@example.com; Dana Hosseini, Iceland Genomics Corporation,
Chief Executive Officer, +354-525-3615, firstname.lastname@example.org